Morinaga N, Adamik R, Moss J, Vaughan M
Pulmonary-Critical Care Medicine Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Biol Chem. 1999 Jun 18;274(25):17417-23. doi: 10.1074/jbc.274.25.17417.
A brefeldin A (BFA)-inhibited guanine nucleotide-exchange protein (GEP) for ADP-ribosylation factors (ARF) was purified earlier from bovine brain cytosol. Cloning and expression of the cDNA confirmed that the recombinant protein (p200) is a BFA-sensitive ARF GEP. p200 contains a domain that is 50% identical in amino acid sequence to a region in yeast Sec7, termed the Sec7 domain. Sec7 domains have been identified also in other proteins with ARF GEP activity, some of which are not inhibited by BFA. To identify structural elements that influence GEP activity and its BFA sensitivity, several truncated mutants of p200 were made. Deletion of sequence C-terminal to the Sec7 domain did not affect GEP activity. A protein lacking 594 amino acids at the N terminus, as well as sequence following the Sec7 domain, also had high activity. The mutant lacking 630 N-terminal amino acids was, however, only 1% as active, as was the Sec7 domain itself (mutant lacking 697 N-terminal residues). It appears that the Sec7 domain of p200 contains the catalytic site but additional sequence (perhaps especially that between positions 595 and 630) modifies activity dramatically. Myristoylated recombinant ARFs were better than non-myristoylated as substrates; ARFs 1 and 3 were better than ARF5, and no activity was detected with ARF6. Physical interaction of the Sec7 domain with an ARF1 mutant was demonstrated, but it was much weaker than that of the cytohesin-1 Sec7 domain with the same ARF protein. Effects of BFA on p200 and all mutants with high activity were similar with approximately 50% inhibition at </=50 microM. The inactive BFA analogue B36 did not inhibit the Sec7 domain or p200. Thus, the Sec7 domain of p200, like that of Sec7 itself (Sata, M., Donaldson, J. G., Moss, J., and Vaughan, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4204-4208), plays a role in BFA inhibition as well as in GEP activity, although the latter is markedly modified by other structural elements.
一种之前从牛脑细胞质中纯化得到的布雷菲德菌素A(BFA)抑制的ADP核糖基化因子(ARF)鸟嘌呤核苷酸交换蛋白(GEP)。cDNA的克隆和表达证实重组蛋白(p200)是一种对BFA敏感的ARF GEP。p200含有一个结构域,其氨基酸序列与酵母Sec7中的一个区域有50%的同源性,该区域被称为Sec7结构域。在其他具有ARF GEP活性的蛋白质中也鉴定出了Sec7结构域,其中一些不受BFA抑制。为了确定影响GEP活性及其对BFA敏感性的结构元件,构建了几个p200的截短突变体。Sec7结构域C端序列的缺失不影响GEP活性。一个在N端缺少594个氨基酸以及Sec7结构域之后序列的蛋白也具有高活性。然而,缺少630个N端氨基酸的突变体活性仅为1%,Sec7结构域本身(缺少697个N端残基的突变体)也是如此。似乎p200的Sec7结构域包含催化位点,但额外的序列(可能特别是595位和630位之间的序列)会显著改变活性。肉豆蔻酰化的重组ARF作为底物比未肉豆蔻酰化的更好;ARF1和ARF3比ARF5更好,且未检测到ARF6的活性。证实了Sec7结构域与ARF1突变体之间存在物理相互作用,但比胞质衔接蛋白-1的Sec7结构域与相同ARF蛋白之间的相互作用弱得多。BFA对p200和所有高活性突变体的影响相似,在≤50μM时约有50%的抑制作用。无活性的BFA类似物B36不抑制Sec7结构域或p200。因此,p200的Sec7结构域与Sec7本身的结构域一样(Sata, M., Donaldson, J. G., Moss, J., and Vaughan, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4204 - 4208),在BFA抑制以及GEP活性中发挥作用,尽管后者会被其他结构元件显著修饰。